This living guideline is being produced by the Australia and New Zealand Musculoskeletal (ANZMUSC) Clinical Trials Network, the Australian Rheumatology Association (ARA) and Cochrane Musculoskeletal.

The guideline seeks to present the best available, current scientific evidence for pharmacological management of the most common forms of IA, namely rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). Topics and questions identified as having highest clinical relevance to medical practitioners who treat IA are being prioritised. These questions include choice of disease-modifying anti-rheumatic drug (DMARD), switching, combination therapy, down-titration of treatment and perioperative DMARD use, as well as the management of other medications, such as opioids and vaccination. As a living guideline, questions will continue to be addressed, new recommendations developed, and existing recommendations updated on an ongoing basis. Recommendations are intended as guides to courses of action subject to clinical judgement and patient preferences.

Versions 1.0 and 2.0 of this living guideline were approved by the National Health and Medical Research Council (NHMRC) on 7 July 2021 and 5 August 2022 respectively. Approval of 'Version 3.0' is now being sought under section 14A of the NHMRC Act 1992. The approval process requires a public consultation period (legislated minimum of 30 days) to allow relevant authorities and stakeholders the opportunity to provide feedback about the draft guideline, thereby contributing to its development.

The following survey is focussed on the new (draft) sections of the guideline but also provides opportunity for comments to be made about any other guideline sections. Where you have no comments to make, simply move to the next question until you reach the end of the survey.

To view the living guideline online (in MAGICapp), please click HERE.

Please provide your feedback by 30 April, 2023 (last date for submissions).

Thank you for your interest and time.